Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis with rVWF in Severe Von Willebrand Disease
NCT02973087Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Takeda. Primary endpoint: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (On-study ABR / Historical ABR) at 12 months. Started Nov 2017; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT02973087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973087.